Effect of requiring advance approval of chemotherapy on number and cost of ungiven doses

American Journal of Health-System Pharmacy

Volumn 68, Issue 7, 2011, Pages 557-558

  Berhoune, Malik ^a   Aboudagga, Haïl ^a   Jacob, Aude ^a   Grandhaye, Jean Pierre ^b   Dayot, Corinne ^a   Prognon, Patrice ^a   Bonan, Brigitte ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CLINICAL PHARMACY; DRUG APPROVAL; DRUG COST; HUMAN; LETTER; ONCOLOGY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; WORKLOAD;

EID: 79956038507     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090664     Document Type: Letter

References (3)

1. Vandenbroucke J, Robays H. Economic impact of the preparation scenario for cytotoxic drugs: an observational study. Eur J Hosp Pharm. 2008; 5:37-42.
2. Salberg DJ, Newton RW, Leduc DT. Cost of wastage in a hospital intravenous admixture program. Hosp Formul. 1984; 19: 375-8.
3. Demesmay K, Limat S, Tissot E et al. Analysis and factors related to the wastage of cytotoxic preparations in a centralised reconstitution unit. J Pharm Clin. 2001; 20: 114-7. (Pubitemid 32692076)